Lead Sponsor

Novartis Pharmaceuticals

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

•Body mass index (BMI) within the range of 30 to 45 kg/m2, inclusive, with ethnic adjustment (≥27.5 kg/m2 for Asian individuals).
•Fasting triglyceride 150 - 500 mg/dL (1.69 - 5.65 mmol/L), inclusive, at screening.
•Able to communicate well with the investigator, to understand and comply with the requirements of the study.

•History of hepatobilliary disease.
•Liver disease or liver injury as indicated by abnormal liver function tests.
•Chronic infection with Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV).
•Fasting triglycerides greater than or equal to 500 mg/dL \[5.65 mmol/L\], or concomitant use of drug treatment for hypertriglyceridemia (fibrates, omega-3 fatty acids, nicotinic acid).
•History of pancreatic injury or pancreatitis.
•History of hypersensitivity to drugs of similar biological class, FGF21 protein analogue, or Fc fusion proteins.
•History of bone disorders or low vitamin D level.
•Contraindications to MRI.
•Change in body weight (more than 5% self-reported OR 5 kg self-reported change during the previous 3 months).
•Use of weight loss drugs.
•Enrollment in a diet, weight loss or exercise programs.

Related studies

NCT06894498 · Obesity and Obesity-related Medical Conditions, Weight Loss

NCT05124808 · Gestational Diabetes, Pregnancy, High Risk, and more

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

NCT07595549 · Obesity, Overweight and/or Obesity, and more

NCT07284875 · Obesity, Overweight

Safety Study of LLF580 in Obese Volunteers